The first patient has been enrolled in a global Phase 2b trial of Evommune, Inc.’s EVO756, an orally available, highly potent, and selective small-molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2), in adults with moderate-to-severe chronic spontaneous urticaria (CSU).
“The dual mechanism of EVO756, which has been shown in preclinical studies to address MRGPRX2 activation on both mast cells and peripheral sensory neurons, represents a promising new therapeutic approach for CSU and a broad range of other inflammatory diseases for which new treatments are urgently needed. Building upon these studies and our previously disclosed EVO756 clinical proof-of-concept data, we are pleased to have the Phase 2b CSU trial now underway. In addition, we are planning to initiate a separate Phase 2b trial of EVO756, in atopic dermatitis, later this year,” says Luis Peña, President and CEO at Evommune, in a news release.
EVO756 is being evaluated in a global, multi-center, Phase 2b randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety in adults with moderate-to-severe CSU. Approximately 160 patients will be enrolled, and patients will be randomized to receive one of three active dose regimens or placebo.
“Enrollment of our open-label Phase 2 chronic inducible urticaria trial is nearly complete, and we believe the pharmacokinetic, pharmacodynamic, and safety data generated on EVO756 warrant the initiation of our Phase 2b trial, and we look forward to reporting the CSU data in 2026,” adds Eugene Bauer, MD, Chief Medical Officer at Evommune.
